4SC & Immunic Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838
4SC AG (FSE Prime Standard: VSC), and Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the signing of an agreement under which Mehr